Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SWAV Stock Summary
Top 10 Correlated ETFs
SWAV
In the News
Shockwave Medical rallies as J&J mulls purchase
Shockwave Medical shares are trading more than 3% higher in Wednesday's session, having soared more than 10% since it was announced Johnson & Johnson (NYSE:JNJ) was considering buying it. The maker of medical devices to treat heart diseases was reported to be an acquisition target for the healthcare giant on Tuesday by the Wall Street Journal.
Shockwave Medical shares rise on report of acquisition talks with Johnson & Johnson
Shares of medical-device maker Shockwave Medical Inc. rose Tuesday following a report that Johnson & Johnson was in talks to acquire the company.
Johnson & Johnson considers deal to buy Shockwave Medical, WSJ reports
Johnson & Johnson is in talks to buy medical device maker Shockwave Medical , the Wall Street Journal reported on Tuesday.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
What Makes Shockwave Medical (SWAV) a Strong Momentum Stock: Buy Now?
Does Shockwave Medical (SWAV) have what it takes to be a top stock pick for momentum investors? Let's find out.
General Motors, Celsius Lead Five Non-AI Stocks Near Buy Points
Turnaround play General Motors and hot energy drink maker Celsius Holdings lead this weekend's watchlist.
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical, Inc. (SWAV) Q4 2023 Earnings Call Transcript
Shockwave Medical, Inc. (SWAV) Q4 2023 Earnings Call Transcript
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
Shockwave Medical (SWAV) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $3.71 per share a year ago.
SWAV Financial details
SWAV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.8 | 2.05 | 6.76 | 12.93 | 19.89 | |
Net income per share | -2.14 | -1.99 | -0.26 | 5.7 | 4.01 | |
Operating cash flow per share | -2.01 | -2.16 | 0.43 | 3.11 | 5.34 | |
Free cash flow per share | -2.17 | -2.51 | 0.07 | 2.44 | 4.51 | |
Cash per share | 8.17 | 6.13 | 5.73 | 8.04 | 26.99 | |
Book value per share | 8.06 | 6.83 | 6.89 | 13.5 | 18.22 | |
Tangible book value per share | 8.06 | 6.83 | 6.89 | 13.5 | 14.61 | |
Share holders equity per share | 8.06 | 6.83 | 6.89 | 13.5 | 18.22 | |
Interest debt per share | 0.99 | 0.79 | 1.38 | 1.64 | 20.21 | |
Market cap | 1.05B | 3.42B | 6.26B | 7.79B | 6.99B | |
Enterprise value | 933.57M | 3.4B | 6.22B | 7.69B | 7.44B | |
P/E ratio | -20.54 | -52.12 | -685.1 | 36.06 | 47.49 | |
Price to sales ratio | 24.46 | 50.51 | 26.39 | 15.9 | 9.58 | |
POCF ratio | -21.82 | -48.1 | 416.27 | 66.16 | 35.68 | |
PFCF ratio | -20.22 | -41.4 | 2.41K | 84.11 | 42.27 | |
P/B Ratio | 5.45 | 15.17 | 25.88 | 15.23 | 10.46 | |
PTB ratio | 5.45 | 15.17 | 25.88 | 15.23 | 10.46 | |
EV to sales | 21.75 | 50.14 | 26.22 | 15.71 | 10.18 | |
Enterprise value over EBITDA | -18.86 | -52.77 | -803.34 | 62.69 | 42.17 | |
EV to operating cash flow | -19.41 | -47.75 | 413.48 | 65.34 | 37.93 | |
EV to free cash flow | -17.98 | -41.1 | 2.39K | 83.07 | 44.95 | |
Earnings yield | -0.05 | -0.02 | 0 | 0.03 | 0.02 | |
Free cash flow yield | -0.05 | -0.02 | 0 | 0.01 | 0.02 | |
Debt to equity | 0.12 | 0.11 | 0.2 | 0.12 | 1.1 | |
Debt to assets | 0.1 | 0.09 | 0.14 | 0.09 | 0.47 | |
Net debt to EBITDA | 2.35 | 0.4 | 5.43 | -0.78 | 2.51 | |
Current ratio | 9.03 | 9.63 | 5.54 | 7.25 | 11.76 | |
Interest coverage | -54.91 | -54.18 | -0.79 | 65.82 | 26.79 | |
Income quality | 0.94 | 1.08 | -1.65 | 0.55 | 1.33 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.03 | 0 | 0.03 | 0.04 | |
Sales general and administrative to revenue | 0.33 | 0.35 | 0.15 | 0.12 | 0.13 | |
Research and developement to revenue | 0.77 | 0.54 | 0.21 | 0.17 | 0.2 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.08 | |
Capex to operating cash flow | 0.08 | 0.16 | -0.83 | -0.21 | -0.16 | |
Capex to revenue | -0.09 | -0.17 | -0.05 | -0.05 | -0.04 | |
Capex to depreciation | -1.67 | -3.44 | -2.25 | -5.17 | -2.95 | |
Stock based compensation to revenue | 0.08 | 0.15 | 0.11 | 0.09 | 0.1 | |
Graham number | 19.69 | 17.49 | 6.35 | 41.61 | 40.55 | |
ROIC | -0.23 | -0.25 | 0 | 0.37 | 0.1 | |
Return on tangible assets | -0.22 | -0.24 | -0.03 | 0.33 | 0.1 | |
Graham Net | 7.01 | 5.44 | 4.18 | 6.88 | 6.33 | |
Working capital | 192.69M | 220.72M | 234.27M | 395.89M | 1.12B | |
Tangible asset value | 192.65M | 225.65M | 241.83M | 511.32M | 536.25M | |
Net current asset value | 177.41M | 199.91M | 182.05M | 324.49M | 327.37M | |
Invested capital | 0.12 | 0.11 | 0.2 | 0.12 | 1.1 | |
Average receivables | 5.11M | 9.53M | 24.56M | 54.4M | 92.96M | |
Average payables | 2.14M | 2.13M | 2.49M | 5.12M | 7.79M | |
Average inventory | 8.6M | 20.97M | 36.42M | 59.05M | 91.35M | |
Days sales outstanding | 62.73 | 62.94 | 57.62 | 53.19 | 57.26 | |
Days payables outstanding | 59.35 | 25.49 | 31.01 | 37.74 | 33.93 | |
Days of inventory on hand | 256.83 | 519.2 | 378.56 | 421.81 | 411.68 | |
Receivables turnover | 5.82 | 5.8 | 6.33 | 6.86 | 6.37 | |
Payables turnover | 6.15 | 14.32 | 11.77 | 9.67 | 10.76 | |
Inventory turnover | 1.42 | 0.7 | 0.96 | 0.87 | 0.89 | |
ROE | -0.27 | -0.29 | -0.04 | 0.42 | 0.22 | |
Capex per share | -0.16 | -0.35 | -0.35 | -0.66 | -0.83 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.98 | 4.42 | 4.91 | 5.06 | 5.5 | |
Net income per share | 3.89 | 1.07 | 0.79 | 0.95 | 1.2 | |
Operating cash flow per share | 1.45 | 0.93 | 1.08 | 1.38 | 1.94 | |
Free cash flow per share | 1.14 | 0.73 | 0.85 | 1.2 | 1.72 | |
Cash per share | 8.42 | 11.44 | 7.05 | 24.93 | 26.82 | |
Book value per share | 14.13 | 15.67 | 16.83 | 16.34 | 18.11 | |
Tangible book value per share | 14.13 | 15.67 | 13.16 | 12.71 | 14.52 | |
Share holders equity per share | 14.13 | 15.67 | 16.83 | 16.34 | 18.11 | |
Interest debt per share | 1.7 | 3.85 | 1.63 | 20.85 | 20 | |
Market cap | 7.44B | 7.9B | 10.46B | 7.33B | 7.04B | |
Enterprise value | 7.34B | 7.76B | 10.38B | 7.59B | 7.48B | |
P/E ratio | 13.2 | 50.47 | 90.64 | 52.35 | 39.71 | |
Price to sales ratio | 51.65 | 49.04 | 58.08 | 39.38 | 34.67 | |
POCF ratio | 141.86 | 232.57 | 263.33 | 144.64 | 98.15 | |
PFCF ratio | 179.87 | 295.01 | 337.67 | 166.08 | 110.68 | |
P/B Ratio | 14.55 | 13.84 | 16.96 | 12.19 | 10.52 | |
PTB ratio | 14.55 | 13.84 | 16.96 | 12.19 | 10.52 | |
EV to sales | 50.98 | 48.16 | 57.62 | 40.82 | 36.85 | |
Enterprise value over EBITDA | 160.94 | 187.49 | 307.02 | 159.55 | 156.95 | |
EV to operating cash flow | 140.03 | 228.41 | 261.26 | 149.91 | 104.31 | |
EV to free cash flow | 177.55 | 289.73 | 335.01 | 172.13 | 117.64 | |
Earnings yield | 0.02 | 0 | 0 | 0 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0 | 0.01 | 0.01 | |
Debt to equity | 0.12 | 0.24 | 0.1 | 1.27 | 1.1 | |
Debt to assets | 0.09 | 0.18 | 0.08 | 0.52 | 0.47 | |
Net debt to EBITDA | -2.11 | -3.42 | -2.44 | 5.61 | 9.28 | |
Current ratio | 7.25 | 4.16 | 5.69 | 14.43 | 11.76 | |
Interest coverage | 43.78 | 62.6 | 39.97 | 17.39 | 15.11 | |
Income quality | 0.37 | 0.87 | 1.38 | 1.45 | 1.62 | |
Dividend Yield | 0 | 0.01 | 0.01 | 0 | 0.02 | |
Payout ratio | 0.01 | 2.13 | 2.76 | 0.1 | 3.76 | |
Sales general and administrative to revenue | 0.12 | 0.12 | 0.17 | 0.12 | 0.12 | |
Research and developement to revenue | 0.16 | 0.17 | 0.2 | 0.21 | 0.21 | |
Intangibles to total assets | 0 | 0 | 0.17 | 0.09 | 0.08 | |
Capex to operating cash flow | -0.21 | -0.21 | -0.22 | -0.13 | -0.11 | |
Capex to revenue | -0.08 | -0.04 | -0.05 | -0.04 | -0.04 | |
Capex to depreciation | -7.2 | -4.21 | -3.41 | -2.17 | -2.64 | |
Stock based compensation to revenue | 0.09 | 0.1 | 0.09 | 0.1 | 0.11 | |
Graham number | 35.19 | 19.46 | 17.26 | 18.7 | 22.11 | |
ROIC | 0.22 | 0.05 | 0.04 | 0.02 | 0.02 | |
Return on tangible assets | 0.22 | 0.05 | 0.04 | 0.03 | 0.03 | |
Graham Net | 7.21 | 8.49 | 5.66 | 4.55 | 6.29 | |
Working capital | 395.89M | 448.83M | 376.14M | 1.05B | 1.12B | |
Tangible asset value | 511.32M | 570.69M | 482.43M | 467.68M | 536.25M | |
Net current asset value | 324.49M | 378.27M | 286.67M | 255.83M | 327.37M | |
Invested capital | 0.12 | 0.24 | 0.1 | 1.27 | 1.1 | |
Average receivables | 67.8M | 77.84M | 90.44M | 97.69M | 106.69M | |
Average payables | 5.1M | 8.89M | 11.96M | 9.87M | 7.87M | |
Average inventory | 72.04M | 79.18M | 87.67M | 94.64M | 102.38M | |
Days sales outstanding | 44.6 | 47.11 | 48.24 | 47.81 | 50.79 | |
Days payables outstanding | 34.56 | 47.21 | 47.29 | 25.22 | 31.53 | |
Days of inventory on hand | 386.25 | 355.69 | 338.4 | 356.8 | 382.48 | |
Receivables turnover | 2.02 | 1.91 | 1.87 | 1.88 | 1.77 | |
Payables turnover | 2.6 | 1.91 | 1.9 | 3.57 | 2.85 | |
Inventory turnover | 0.23 | 0.25 | 0.27 | 0.25 | 0.24 | |
ROE | 0.28 | 0.07 | 0.05 | 0.06 | 0.07 | |
Capex per share | -0.31 | -0.2 | -0.24 | -0.18 | -0.22 |
SWAV Frequently Asked Questions
What is ShockWave Medical, Inc. stock symbol ?
ShockWave Medical, Inc. is a US stock , located in Santa clara of Ca and trading under the symbol SWAV
Is ShockWave Medical, Inc. buy or a sell ?
11 stock analysts have 11 predictions with a medium analyst target price of $229.73. The lowest prediction is $175 and the highest is $338
What is SWAV stock prediction ?
What is ShockWave Medical, Inc. stock quote today ?
ShockWave Medical, Inc. stock price is $325.13 today.
Is ShockWave Medical, Inc. stock public?
Yes, ShockWave Medical, Inc. is a publicly traded company.